Loading
BI
Biolase, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 26 May 2023.
Biolase, Inc: what insiders have been doing
Biolase, Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at Biolase, Inc has published a filing in the past twelve months. The most recent one dates from 26 May 2023.
The full history, which starts in 2016, counts 13 purchases against 2 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
18
Thresholds
n/a
Buy Volume
€801,881
13 ops. · all time
Sell Volume
€6,259
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$42.3M
Gross profitUS$14.4M34% margin
Net income-US$17.8M-42.0% margin
Last declaration on 26 May 2023
Declarations18 total
1,307,931 shares@ US$0.61100.0% of flowCommon StockSEC:0000908834-23-000047:0
Canonical exit: 11 May 2020 (T+90)
3,537 shares@ US$0.75100.0% of flowCommon StockSEC:0001209191-22-060435:0
554.794 sharesSeries G Preferred StockSEC:0000899243-22-016094:0
345.863 sharesSeries G Preferred StockSEC:0000899243-22-016097:0
1,395.41 sharesSeries G Preferred StockSEC:0000899243-22-016099:0
11,038 shares@ US$0.38100.0% of flowCommon StockSEC:0001209191-21-070069:0
70,000 shares@ US$0.4539.4% of flowCommon StockSEC:0001209191-21-067673:0
Canonical exit: 28 Feb 2022 (T+90)
35,000 shares@ US$0.6125.8% of flowCommon StockSEC:0001209191-21-052884:0
Canonical exit: 18 Nov 2021 (T+90)
40,000 shares@ US$0.7534.8% of flowCommon StockSEC:0001209191-21-033957:0
Canonical exit: 17 Aug 2021 (T+90)
18,580 sharesCommon StockSEC:0001140361-16-052726:0
Canonical exit: 11 May 2016 (T+90)
500 sharesCommon StockSEC:0001140361-16-052726:1
Canonical exit: 12 May 2016 (T+90)
13,026 sharesCommon StockSEC:0001140361-16-051675:0
Canonical exit: 9 May 2016 (T+90)
54,187 sharesCommon StockSEC:0001140361-16-051675:1
Canonical exit: 10 May 2016 (T+90)
1,400 sharesCommon StockSEC:0001140361-16-048778:0
Canonical exit: 24 Apr 2016 (T+90)
4,800 sharesCommon StockSEC:0001140361-16-048525:0
Canonical exit: 20 Apr 2016 (T+90)
1,870 sharesCommon StockSEC:0001140361-16-048525:1
Canonical exit: 21 Apr 2016 (T+90)
4,300 sharesCommon StockSEC:0001140361-16-048297:0
Canonical exit: 18 Apr 2016 (T+90)
19,900 sharesCommon StockSEC:0001140361-16-048297:1
Canonical exit: 19 Apr 2016 (T+90)
18 of 18 declarations
About Biolase, Inc
Biolase, Inc. is a United States-based medical device company listed on the NASDAQ (ticker: BIOL). The company operates in the dental technology niche, with a core focus on laser systems used in dentistry and, to a lesser extent, adjacent medical applications. Its business model centers on designing, manufacturing, marketing, and selling laser-based equipment to dental professionals, clinics, and distributors. BIOLASE’s principal executive offices are in Lake Forest, California.
The company’s origins date back to 1984, when it was founded in Marseille, France, under the name Societe Endo Technic, SA. It later went through a corporate evolution in the United States, becoming BIOLASE Technology, Inc. in 1994 and BIOLASE, Inc. in 2012. That history is relevant for investors because it shows a long-standing technological and commercial orientation toward laser dentistry rather than a broad, diversified medtech platform.
Read moreShow less
BIOLASE’s product portfolio is built around the Waterlase family of all-tissue dental lasers and the Epic line of soft-tissue diode lasers. Waterlase systems are positioned for hard tissue, soft tissue, and bone indications, while Epic products address soft-tissue surgery, hygiene procedures, pain therapy, and whitening. The company’s value proposition is straightforward: help dentists perform minimally invasive procedures that can reduce discomfort, bleeding, and recovery time, while expanding the range of procedures a practice can offer. In commercial terms, this supports both patient appeal and practice economics.
From a competitive standpoint, BIOLASE is a specialist rather than a broad-based dental equipment manufacturer. Its market position depends on product differentiation, clinical credibility, intellectual property, and the ability to convert dentists to laser-based workflows. The company has historically emphasized its installed base and international reach, stating that it has sold products in more than 80 countries. That gives it geographic breadth, even though the United States remains a key market and its financial reporting and capital-markets activity are centered on the U.S.
Recent developments matter for investors. BIOLASE has continued to raise capital through equity financings, including transactions in late 2023 and early 2024, reflecting ongoing funding needs. Its 2023 annual report disclosed recurring losses and a going-concern warning, underscoring balance-sheet pressure and execution risk. At the same time, BIOLASE has continued to refresh its product messaging, including the latest Waterlase iPlus generation and trade-show demonstrations focused on periodontal and implant care. Overall, BIOLASE remains a highly focused dental-laser player on the NASDAQ in the United States, with technology differentiation but material financial and liquidity challenges.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
